HC Wainwright Reaffirms Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

HC Wainwright reiterated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT - Free Report) in a research report released on Monday, Benzinga reports. The brokerage currently has a $20.00 price objective on the stock.

Checkpoint Therapeutics Price Performance

Shares of Checkpoint Therapeutics stock traded up $0.04 during midday trading on Monday, reaching $2.34. The company had a trading volume of 498,951 shares, compared to its average volume of 448,253. The stock has a fifty day moving average price of $2.32 and a 200 day moving average price of $2.02. Checkpoint Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $3.62. The firm has a market cap of $105.35 million, a PE ratio of -0.86 and a beta of 1.29.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.11. The firm had revenue of $0.04 million during the quarter. As a group, sell-side analysts forecast that Checkpoint Therapeutics will post -0.81 EPS for the current year.

Insiders Place Their Bets

In other news, CFO William Garrett Gray sold 13,038 shares of Checkpoint Therapeutics stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $2.06, for a total value of $26,858.28. Following the completion of the transaction, the chief financial officer now directly owns 672,186 shares in the company, valued at $1,384,703.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 13,038 shares of the stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $2.06, for a total value of $26,858.28. Following the sale, the chief financial officer now directly owns 672,186 shares in the company, valued at approximately $1,384,703.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James F. Oliviero III sold 24,610 shares of the business's stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $2.05, for a total value of $50,450.50. Following the transaction, the chief executive officer now owns 1,977,170 shares of the company's stock, valued at $4,053,198.50. The disclosure for this sale can be found here. Company insiders own 2.10% of the company's stock.

Hedge Funds Weigh In On Checkpoint Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in shares of Checkpoint Therapeutics in the 2nd quarter worth approximately $34,000. Lindbrook Capital LLC bought a new stake in Checkpoint Therapeutics in the first quarter worth $62,000. 180 Wealth Advisors LLC purchased a new stake in Checkpoint Therapeutics during the 2nd quarter valued at about $96,000. Choreo LLC increased its position in shares of Checkpoint Therapeutics by 200.9% during the first quarter. Choreo LLC now owns 57,922 shares of the company's stock valued at $119,000 after acquiring an additional 38,672 shares in the last quarter. Finally, PVG Asset Management Corp bought a new position in shares of Checkpoint Therapeutics during the second quarter valued at $295,000. Institutional investors own 22.00% of the company's stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.